Eli Lilly and Company
NYSE:LLYDrug Manufacturers - General
-$10.54 today
- Market cap
- $1.30T
- Beta
- 0.52
- P/E (TTM)
- 39.0
- EPS (TTM)
- $28.26
- Dividend yield
- 0.59%
Volume 2.58M
Average 3.19M
LLY EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Eli Lilly and CompanyNYSE: LLY
EPS (Diluted) · Q2 FY2026 · quarter ended Jun 2026
EPS (Diluted) grows, but more slowly than its trailing trend
Q2 FY2026 EPS (Diluted) of $7.94 rose 26.2% year over year, behind the +94.8% change in trailing-twelve-month EPS (Diluted). Sequentially, it fell 3.9% from the prior quarter. Over 3 fiscal years it compounded at +51.7% a year.
Context
- EPS (Diluted) increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 15 analysts of $35.45 (+54.5%) for the fiscal year ending Dec 2026, a slowdown from the +96.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $7.94-3.9% QoQ
- Last fiscal yearDec 2025
- $22.95+96.0% YoY
- LTMJun 2026
- $29.8+94.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +26.2% | -8.0% | -34.3 pp |
| 1 year | +96.0% | +54.5% | -41.5 pp |
| 3-year CAGR | +51.7% | +36.2% | -15.6 pp |
| 5-year CAGR | +26.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- 22.95 USD
- Year-over-year change
- +96.0%
- 4-year CAGR
- +40.7%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.95 | +96.0% |
| FY2024 | 2024-12-31 | 11.71 | +101.9% |
| FY2023 | 2023-12-31 | 5.80 | -11.7% |
| FY2022 | 2022-12-31 | 6.57 | +12.3% |
| FY2021 | 2021-12-31 | 5.85 | — |
EPS (Diluted) vs competitors
How LLY compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
- Its year-over-year change of +94.8% is the 2nd highest of 10, against a peer median of -3.4%.
- Over three fiscal years its annual growth of +51.7% compares with a peer median of +8.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $29.8 USD | +94.8% | +51.7% | |
| LTM Jun 2026 | DKK 26.19 DKK | +5.0% | +23.5% | |
| LTM Jun 2026 | $16.09 USD | +31.6% | +5.5% | |
| LTM Sep 2026 | $7.01 USD | +16.4% | +45.8% | |
| LTM Jun 2026 | $6.63 USD | -3.4% | +31.4% | |
| LTM Sep 2026 | $6.6 USD | -36.3% | +17.9% | |
| LTM Sep 2026 | $5.83 USD | +338.0% | -29.0% | |
| LTM Jun 2026 | $1.25 USD | -80.7% | +8.4% | |
| LTM Jun 2026 | $0.76 USD | -59.9% | -37.1% | |
| LTM Jun 2026 | €0.49 EUR | -87.2% | +0.2% | |
| Peer median (excluding LLY) | — | -3.4% | +8.4% | |
Competitors are the stored peer set for LLY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 28.32B | 28.54B | 34.12B | 45.04B | 65.18B |
| Cost of Revenue | 7.31B | 6.63B | 7.08B | 8.42B | 11.05B |
| Gross Profit | 21.01B | 21.91B | 27.04B | 36.63B | 54.13B |
| Gross Margin | 74.2% | 76.8% | 79.2% | 81.3% | 83.0% |
| Research & Development | 6.93B | 7.19B | 9.31B | 10.99B | 13.34B |
| Selling, General & Admin | 6.14B | 6.07B | 6.94B | 8.59B | 11.09B |
| Operating Expenses | 13.07B | 13.26B | 16.25B | 19.59B | 24.43B |
| Depreciation & Amortization | 1.55B | 1.52B | 1.53B | 1.77B | 2B |
| EBITDA | 8.04B | 8.66B | 8.57B | 18.81B | 31.69B |
| EBITDA Margin | 28.4% | 30.3% | 25.1% | 41.8% | 48.6% |
| Operating Income | 7.93B | 8.65B | 10.79B | 17.04B | 29.7B |
| Operating Margin | 28.0% | 30.3% | 31.6% | 37.8% | 45.6% |
| Interest Income | 25.4M | 62.8M | 173.6M | 175.2M | 153.3M |
| Interest Expense | 339.8M | 331.6M | 485.9M | 780.6M | 795.3M |
| Other Income / Expenses | (1.78B) | (1.85B) | (4.23B) | (4.36B) | (3.97B) |
| Income Before Tax | 6.16B | 6.81B | 6.55B | 12.68B | 25.73B |
| Pre-Tax Margin | 21.7% | 23.8% | 19.2% | 28.2% | 39.5% |
| Income Tax Expense | 573.8M | 561.6M | 1.31B | 2.09B | 5.09B |
| Net Income | 5.58B | 6.24B | 5.24B | 10.59B | 20.64B |
| Net Margin | 19.7% | 21.9% | 15.4% | 23.5% | 31.7% |
| EPS (Basic) | 5.85 | 6.57 | 5.83 | 11.76 | 23.07 |
| EPS (Diluted) | 5.85 | 6.57 | 5.80 | 11.71 | 22.95 |
| Weighted Avg Shares | 953.65M | 950.18M | 899.38M | 900.61M | 898M |
| Weighted Avg Shares (Diluted) | 953.65M | 950.18M | 903.28M | 904.06M | 898M |
Eli Lilly and Company
NYSE:LLY
Intrinsic Alpha fair value
Locked
Current Price
$1,382.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.